Literature DB >> 31904927

Combined Magnetoliposome Formation and Drug Loading in One Step for Efficient Alternating Current-Magnetic Field Remote-Controlled Drug Release.

Maria Eugenia Fortes Brollo1, Ana Domínguez-Bajo1, Andrea Tabero2, Vicente Domínguez-Arca3, Victor Gisbert1, Gerardo Prieto3, Christer Johansson4, Ricardo Garcia1, Angeles Villanueva2,5, María Concepción Serrano1, María Del Puerto Morales1.   

Abstract

We have developed a reproducible and facile one step strategy for the synthesis of doxorubicin loaded magnetoliposomes by using a thin-layer evaporation method. Liposomes of around 200 nm were made of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and iron oxide nanoparticles (NPs) with negative, positive, and hydrophobic surfaces that were incorporated outside, inside, or between the lipid bilayers, respectively. To characterize how NPs are incorporated in liposomes, advanced cryoTEM and atomic force microscope (AFM) techniques have been used. It was observed that only when the NPs are attached outside the liposomes, the membrane integrity is preserved (lipid melt transition shifts to 38.7 °C with high enthalpy 34.8 J/g) avoiding the leakage of the encapsulated drug while having good colloidal properties and the best heating efficiency under an alternating magnetic field (AMF). These magnetoliposomes were tested with two cancer cell lines, MDA-MB-231 and HeLa cells. First, 100% of cellular uptake was achieved with a high cell survival (above 80%), which is preserved (83%) for doxorubicin-loaded magnetoliposomes. Then, we demonstrate that doxorubicin release can be triggered by remote control, using a noninvasive external AMF for 1 h, leading to a cell survival reduction of 20%. Magnetic field conditions of 202 kHz and 30 mT seem to be enough to produce an effective heating to avoid drug degradation. In conclusion, these drug-loaded magnetoliposomes prepared in one step could be used for drug release on demand at a specific time and place, efficiently using an external AMF to reduce or even eliminate side effects.

Entities:  

Keywords:  HeLa cells; MDA-MB-231 cells; doxorubicin; drug delivery carrier; magnetic hyperthermia; magnetoliposomes; superparamagnetic iron oxide nanoparticle

Mesh:

Substances:

Year:  2020        PMID: 31904927     DOI: 10.1021/acsami.9b20603

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  5 in total

1.  One-Step Microfluidic Fabrication of Multi-Responsive Liposomes for Targeted Delivery of Doxorubicin Synergism with Photothermal Effect.

Authors:  Songwei Lv; Ran Jing; Xiaowu Liu; Honglei Shi; Yunfeng Shi; Xugang Wang; Xiubo Zhao; Kai Cao; Zhong Lv
Journal:  Int J Nanomedicine       Date:  2021-11-23

2.  Thermosensitive Betulinic Acid-Loaded Magnetoliposomes: A Promising Antitumor Potential for Highly Aggressive Human Breast Adenocarcinoma Cells Under Hyperthermic Conditions.

Authors:  Claudia Geanina Farcas; Cristina Dehelean; Iulia Andreea Pinzaru; Marius Mioc; Vlad Socoliuc; Elena-Alina Moaca; Stefana Avram; Roxana Ghiulai; Dorina Coricovac; Ioana Pavel; Praveen Kumar Alla; Octavian Marius Cretu; Codruta Soica; Felicia Loghin
Journal:  Int J Nanomedicine       Date:  2020-10-23

3.  A Novel Hybrid Nanosystem Integrating Cytotoxic and Magnetic Properties as a Tool to Potentiate Melanoma Therapy.

Authors:  Nuno Cruz; Jacinta Oliveira Pinho; Graça Soveral; Lia Ascensão; Nuno Matela; Catarina Reis; Maria Manuela Gaspar
Journal:  Nanomaterials (Basel)       Date:  2020-04-06       Impact factor: 5.076

4.  Computational Modeling of Combination of Magnetic Hyperthermia and Temperature-Sensitive Liposome for Controlled Drug Release in Solid Tumor.

Authors:  Masoud H H Tehrani; M Soltani; Farshad Moradi Kashkooli; Mohammadreza Mahmoudi; Kaamran Raahemifar
Journal:  Pharmaceutics       Date:  2021-12-24       Impact factor: 6.321

5.  In Vivo Assimilation of CuS, Iron Oxide and Iron Oxide@CuS Nanoparticles in Mice: A 6-Month Follow-Up Study.

Authors:  Alberto Curcio; Aurore Van de Walle; Christine Péchoux; Ali Abou-Hassan; Claire Wilhelm
Journal:  Pharmaceutics       Date:  2022-01-13       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.